Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group-Reference-Cited by-同舟云学术

Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Published:2013-09-26 Issue:5 Volume:98 Page:578-588
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Tomizawa Daisuke,Tawa Akio,Watanabe Tomoyuki,Saito Akiko Moriya,Kudo Kazuko,Taga Takashi,Iwamoto Shotaro,Shimada Akira,Terui Kiminori,Moritake Hiroshi,Kinoshita Akitoshi,Takahashi Hiroyuki,Nakayama Hideki,Kiyokawa Nobutaka,Isoyama Keiichi,Mizutani Shuki,Hara Junichi,Horibe Keizo,Nakahata Tatsutoshi,Adachi Souichi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-013-1429-2.pdf

Reference21 articles.

1. Pui CH, Ribeiro RC, Campana D, Raimondi SC, Hancock ML, Behm FG, et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia. 1996;10(6):952–6.

2. Ishii E, Okamura J, Tsuchida M, Kobayashi M, Akiyama Y, Nakahata T, et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol. 1991;19(1):28–32.

3. Sorensen PH, Chen CS, Smith FO, Arthur DC, Domer PH, Bernstein ID, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Investig. 1994;93(1):429–37.

4. Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79(12):3325–30.

5. Hauer J, Tosi S, Schuster FR, Harbott J, Kolb HJ, Borkhardt A. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement. Pediatr Blood Cancer. 2008;50(4):921–3.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver fibrosis among infants with t(1;22)(p13;q13) acute megakaryoblastic leukemia: a case report and literature review;Frontiers in Oncology;2024-08-30

2. High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 trial;Pediatric Blood & Cancer;2024-07-02

3. Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms;Blood;2024-06-20

4. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study;International Journal of Hematology;2024-03-09

5. De Novo AML;Pediatric Oncology;2024